These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33516752)

  • 21. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
    Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Miller M; Tardif JC; Ketchum SB; Doyle RT; Murphy SA; Soni PN; Braeckman RA; Juliano RA; Ballantyne CM;
    Clin Cardiol; 2017 Mar; 40(3):138-148. PubMed ID: 28294373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction.
    Huston J; Schaffner H; Cox A; Sperry A; Mcgee S; Lor P; Langley L; Skrable B; Ashchi M; Bisharat M; Gore A; Jones T; Sutton D; Sheikh-Ali M; Berner J; Goldfaden R
    Am J Cardiovasc Drugs; 2023 Jul; 23(4):393-406. PubMed ID: 37188993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding why REDUCE-IT was positive - Mechanistic overview of eicosapentaenoic acid.
    Harris WS
    Prog Cardiovasc Dis; 2019; 62(5):401-405. PubMed ID: 31666183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.
    Gaba P; Bhatt DL; Mason RP; Miller M; Verma S; Steg PG; Boden WE;
    J Clin Lipidol; 2022; 16(4):389-402. PubMed ID: 35773147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
    Szarek M; Bhatt DL; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Mason RP; Ketchum SB; Lira Pineda A; Doyle RT; Steg PG;
    J Am Coll Cardiol; 2024 Apr; 83(16):1529-1539. PubMed ID: 38530686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease.
    Cainzos-Achirica M; Quispe R; Dudum R; Greenland P; Lloyd-Jones D; Rana JS; Lima JAC; Doria de Vasconcellos H; Joshi PH; Khera A; Ayers C; Erbel R; Stang A; Jöckel KH; Lehmann N; Schramm S; Schmidt B; Toth PP; Patel KV; Blaha MJ; Bittencourt M; Nasir K
    JACC Cardiovasc Imaging; 2022 Apr; 15(4):641-651. PubMed ID: 34922873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
    Mosca L; Navar AM; Wenger NK
    J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Am J Med; 2021 Jul; 134(7):e415-e419. PubMed ID: 33450273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
    Bays HE; Ballantyne CM; Braeckman RA; Stirtan WG; Doyle RT; Philip S; Soni PN; Juliano RA
    Metab Syndr Relat Disord; 2015 Aug; 13(6):239-47. PubMed ID: 25893544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
    Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C
    Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
    Ghati N; Roy A; Bhatnagar S; Bhati S; Bhushan S; Mahendran M; Thakur A; Tiwari P; Dwivedi T; Mani K; Gupta R; Mohan A; Garg R; Saxena A; Guleria R; Deepti S
    Trials; 2020 Oct; 21(1):902. PubMed ID: 33126910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?
    Ferrières J; Bataille V; Puymirat E; Schiele F; Simon T; Danchin N;
    Clin Cardiol; 2020 Nov; 43(11):1260-1265. PubMed ID: 32720384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
    Gaba P; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Giugliano RP; Martens FMAC; Gibson CM; Ballantyne CM;
    J Am Coll Cardiol; 2022 May; 79(17):1660-1671. PubMed ID: 35483753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
    Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Icosapent Ethyl: Niche Drug or for the Masses?
    Bazarbashi N; Miller M
    Curr Cardiol Rep; 2020 Aug; 22(10):104. PubMed ID: 32770402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.